宫颈癌术后大分割调强放疗联合同期化疗:POHIM-CCRT非随机对照试验
该多中心2期非随机对照试验纳入84例根治性子宫切除术后具淋巴结转移、宫旁浸润或切缘阳性的宫颈癌患者,评估术后盆腔大分割调强放疗(40 Gy/16次)联合同期化疗的急性毒性。79例可评估患者中,≥3级急性毒性发生2例(2.5% [90% CI, 0%-4.8%]),中位随访43.0个月,3年无病生存率79.3%、总生存率98.0%。
要点
- 术后盆腔大分割调强放疗40 Gy/16次联合同期化疗,≥3级急性毒性发生率为2.5%(90% CI, 0%-4.8%)。
- 中位随访43.0个月,3年无病生存率79.3%,总生存率98.0%。
- 作者认为该方案在宫颈癌术后患者中安全且耐受性良好,但需更长随访评估远期毒性与肿瘤学结局。
核心结论
- 该非随机对照试验结果表明,宫颈癌女性术后采用大分割调强放疗40 Gy/16次行盆腔照射联合同期化疗安全且耐受性良好。
- 需要更长时间随访的研究来评估远期毒性和肿瘤学结局。
研究设计与样本
- POHIM-CCRT研究为多中心、2期非随机对照试验,自2017年6月1日至2023年2月28日入组并随访患者。
- 共从韩国放射肿瘤学组附属的5家机构入组84例患者,其中5例在放疗前退出,最终分析79例患者的数据。
- 纳入标准为确诊宫颈癌根治性子宫切除术后存在淋巴结转移、宫旁浸润或切缘阳性的患者。
- 干预为术后盆腔大分割调强放疗,全盆腔40 Gy分16次,联合同期化疗。
- 主要终点为可评估人群中放疗期间或放疗完成后3个月内≥3级胃肠道、泌尿生殖系统和血液学急性毒性发生率(依据美国国家癌症研究所不良事件通用术语标准4.0版)。
主要发现
- 患者中位(IQR)年龄为48(42-58)岁,中位(IQR)肿瘤大小为3.7(2.7-4.5)cm。
- 79例患者中,31例(39.7%)有淋巴结转移,4例(5.1%)切缘阳性,43例(54.4%)有宫旁浸润。
- ≥3级急性毒性发生于2例患者(2.5% [90% CI, 0%-4.8%])。
- 中位(IQR)随访43.0(21.1-59.0)个月后,3年无病生存率为79.3%,总生存率为98.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长时间随访的研究来评估远期毒性和肿瘤学结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prospective data assessing the safety of hypofractionated (40 Gy in 16 fractions) radiotherapy (RT) among patients who receive postoperative concurrent chemoradiotherapy for cervical cancer are lacking. OBJECTIVE: To evaluate the acute toxic effects of hypofractionated pelvic intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy among women with cervical cancer who underwent radical hysterectomy. DESIGN, SETTING, AND PARTICIPANTS: The POHIM-CCRT (Postoperative Hypofractionated Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer) study was designed as a multicenter, phase 2 nonrandomized controlled trial that accrued and followed up patients from June 1, 2017, to February 28, 2023. In total, 84 patients were enrolled from 5 institutions affiliated with the Korean Radiation Oncology Group. Eligible patients experienced lymph node metastasis, parametrial invasion, or positive resection margins after radical hysterectomy for treatment of confirmed cervical cancer. INTERVENTION: Postoperative pelvic radiation using hypofractionated IMRT with 40 Gy in 16 fractions to the whole pelvis combined with concurrent chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was incidence of acute grade 3 or higher gastrointestinal tract, genitourinary, and hematologic toxic effects (based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0) in the evaluable population during RT or within 3 months after RT completion. RESULTS: Of 84 patients enrolled, 5 dropped out prior to RT, and data from 79 patients were analyzed. The patients' median (IQR) age was 48 (42-58) years, and the median (IQR) tumor size was 3.7 (2.7-4.5) cm. Of these patients, 31 (39.7%) had lymph node metastasis, 4 (5.1%) had positive resection margins, and 43 (54.4%) had parametrial invasion. Grade 3 or higher acute toxic effects occurred in 2 patients (2.5% [90% CI, 0%-4.8%]). After a median (IQR) follow-up of 43.0 (21.1-59.0) months, the 3-year disease-free survival rate was 79.3%, and the overall survival rate was 98.0%. CONCLUSIONS: Findings from this nonrandomized control trial indicated that postoperative pelvic irradiation combined with concurrent chemotherapy using hypofractionated IMRT with 40 Gy in 16 fractions was safe and well-tolerated in women with cervical cancer. Studies assessing long-term toxic effects and oncological outcomes with longer follow-up periods are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03239613.
引用
- Cho WK, Park W, Kim SW, et al. Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 38662364. doi:10.1001/jamaoncol.2024.0565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。